Beam Therapeutics Inc's Suppliers recorded an increase in sales by 8.82 % year on year in Q3 2026, sequentially sales grew by 5.56 %, while their net margin rose to 8.62 % year on year, compared to the previous quarter Beam Therapeutics Inc's Suppliers had a lower net margin at 5.56 %,
Beam Therapeutics Inc's Suppliers recorded an increase in sales by 8.82 % year on year in Q3 2026, sequentially sales grew by 5.56 %, while their net margin rose to 8.62 % year on year, compare to previous quarter BEAM's Suppliers had lower net margin at 8.62 %,
The company sources raw materials from biological sources, which can be challenging to procure and may be subject to contamination or recall, potentially affecting manufacturing and development timelines. It relies on third parties, including contract manufacturing organizations (CMOs), contract research organizations (CROs), clinical data management organizations, medical institutions, and clinical investigators, to manufacture product components, conduct clinical trials, and perform research and preclinical testing. These third parties may terminate their engagements, potentially causing delays. The company remains responsible for compliance with regulatory standards such as Good Clinical Practices and clinical trial registration requirements. Reliance on CROs results in many aspects of development programs being outside the company's direct control.
Beam Therapeutics Inc's Comment on Supply Chain
The company sources raw materials from biological sources, which can be challenging to procure and may be subject to contamination or recall, potentially affecting manufacturing and development timelines. It relies on third parties, including contract manufacturing organizations (CMOs), contract research organizations (CROs), clinical data management organizations, medical institutions, and clinical investigators, to manufacture product components, conduct clinical trials, and perform research and preclinical testing. These third parties may terminate their engagements, potentially causing delays. The company remains responsible for compliance with regulatory standards such as Good Clinical Practices and clinical trial registration requirements. Reliance on CROs results in many aspects of development programs being outside the company's direct control.
BEAM's Suppliers Net Income grew by
BEAM's Suppliers Net margin grew in Q3 to
49.43 %
8.62 %
BEAM's Suppliers Net Income grew by 49.43 %
BEAM's Suppliers Net margin grew in Q3 to 8.62 %
Beam Therapeutics Inc's Suppliers Sales Growth
in Q3 2026 by Industry
Sources:
Beam Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Beam Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
5.08 % 